2024 Bulletin for Subspecialty Certification in Complex Family Planning for Senior Candidates

This Bulletin, issued in August of 2023, represents the official statement of the requirements in effect for the 2024 Complex Family Planning (CFP) Senior Candidate Examination. These requirements only apply to those obstetrician-gynecologists who qualify as senior candidates. 2025 will be the last year ABOG administers the CFP senior candidate examination.

Revised February 28, 2024
TABLE OF CONTENTS

GENERAL INFORMATION FOR ALL CANDIDATES 3
  Gender Language Disclaimer 3
  Non-Discrimination and Fairness Disclaimer 3
  Candidate Responsibility 3
  Senior Candidates 3
  The Division of Complex Family Planning (CFP) 4

2024 SENIOR CANDIDATE EXAMINATION 4
  Introduction 4
  Eligibility Requirements 4
  More on Case Logs 6
  Application Process 6
  Applicants Ruled Not Admissible 7
  Deadlines and Fees 8
  Administration of the Senior Candidate Examination 8
  Test Security 9
  Senior Candidate Examination Content 10
  Results and Scoring 11
  Rescores and Appeals 12
  Requests for Re-Examination 12
  Length of Certification 12

CERTIFYING (ORAL) EXAMINATION 13

APPENDIX A: ABOG DIVISION OF COMPLEX FAMILY PLANNING 13
APPENDIX B: CASE LOG 14
APPENDIX C: CANDIDATE DISABILITY 16
APPENDIX D: LACTATION ACCOMMODATIONS 17
APPENDIX E: CFP SENIOR CANDIDATE EXAMINATION TOPICS 18
  Contraception 18
  Early Pregnancy Evaluation and Management 19
  Abortion/Pregnancy Termination 20
  Research, Health Policy, and Advocacy 22
  Core Competencies and Cross Content 23

Appendix F: APPROVED ABBREVIATIONS FOR ABOG EXAMINATIONS 24
GENERAL INFORMATION FOR ALL CANDIDATES

Gender Language Disclaimer

The American Board of Obstetrics and Gynecology (ABOG) recognizes that patients have diverse gender identities and is striving to use gender-inclusive language in its publications, literature, and other printed and digital materials. In some instances, ABOG uses the word “woman” (and the pronouns “she” and “her”) to describe patients or individuals whose sex assigned at birth was female, whether they identify as female, male, or non-binary. As gender language continues to evolve in the scientific and medical communities, ABOG will periodically reassess this usage and will make appropriate adjustments as necessary. When describing or referencing study populations used in research, ABOG will use the gender terminology reported by the study investigators.

Non-Discrimination and Fairness Disclaimer

The American Board of Obstetrics and Gynecology does not discriminate on the basis of race, color, creed, age, gender, national origin, religion, disability, marital status, parental status, ancestry, sexual orientation, or any other status protected by law. All candidates for certification will be treated in an equitable manner throughout the certification process and judged solely on the criteria determined by the American Board of Obstetrics and Gynecology.

Candidate Responsibility

The process of certification in Complex Family Planning (CFP) by the American Board of Obstetrics and Gynecology is voluntary. ABOG does not assume responsibility to contact potential candidates. Rather, each candidate is responsible for initiating the process, completing all applications, submitting required materials by the deadlines, and paying the appropriate fees.

ABOG annually reviews policies and procedures for determining applicant and candidate certification requirements, as well as compliance with these requirements based on industry standards. Candidates must meet the eligibility requirements published in the Bulletin dated for the year in which they are to take the CFP Senior Candidate Examination as requirements may change from year to year. The Bulletin is available online at www.abog.org under the “Bulletins & Dates” tab. It is the candidate’s responsibility to become familiar with all the material contained in the Bulletin, including the information in the Appendices. Each candidate is also responsible for reading all the policies included in the Policies section under the “About ABOG” tab on the ABOG home page. It is each candidate’s responsibility to be familiar with all the information included in the “Subspecialty Certification” tab on the ABOG website at www.abog.org.

After applying, it is the responsibility of each candidate to update their personal email and mailing addresses in the profile section of their ABOG portal. Because hospital and university email addresses are often closed after the completion of training, candidates should list a personal email address.

Senior Candidates

A “senior candidate” is a physician who is applying for the Senior Candidate Examination in CFP on the basis of experience and clinical practice. Candidates who complete fellowship training by
September 30, 2022, are considered senior candidates and must meet the requirements listed in this Bulletin. Candidates who entered a two-year fellowship in CFP approved by ACGME on July 1, 2021, and thereafter are not eligible to apply as senior candidates.

Certification for senior candidates requires passing only a computer-based examination to be board-certified in CFP. All senior candidates must have passed both the qualifying and certifying specialty examinations. They must be current, active ABOG Diplomates at the time of application for the CFP Senior Candidate Examination and must remain so at the time of the written examination. The eligibility of senior candidates to become ABOG CFP-certified expires after the 2025 examination. No application will be accepted for certification based on “senior” status after that date, regardless of experience or training.

The Division of Complex Family Planning (CFP)

The members of the Division of Complex Family Planning are listed in Appendix A.

2024 SENIOR CANDIDATE EXAMINATION

Introduction

The process of certification by ABOG is voluntary. The ABOG CFP Senior Candidate Examination is one-step certification process, comprising a computer-based multiple-choice examination.

Each potential candidate is responsible for completing the application for the CFP Senior Candidate Examination online at www.abog.org, submitting all required materials to ABOG at the time they are requested, and meeting all deadlines. ABOG will make the final decision concerning the applicant’s admission to the examination after considering all circumstances affecting the application.

Eligibility Requirements

Each of the following is a requirement for a senior candidate in CFP to sit for the subspecialty Senior Candidate Examination. The candidate must meet all the requirements in effect, at the time of application, within the year for which admission to the Senior Candidate Examination is requested.

1. **Training and Practice** In order to qualify as a CFP senior candidate, a physician must meet one of the following 2 criteria:

   The **physician must have been practicing CFP for a minimum of 3 years post-residency training.** During the most recent 3 years, a minimum of 30% of the physician’s total outpatient and inpatient practice must consist of patients related to the area of CFP.

   **OR**

   **Completion of a CFP fellowship by September 30, 2022, but not practicing for a minimum of 3 years.** These physicians must submit an affidavit signed by either the current fellowship Program Director or the or the Chair of the Department of Obstetrics and Gynecology that attests to their successful completion of the training program.
2. **Diplomate Status** A senior candidate must be a diplomate of ABOG and hold an Active Certificate in Obstetrics and Gynecology.

3. **Unrestricted License** A senior candidate must hold an unrestricted license to practice medicine in all states or territories of the United States or Canada in which the candidate holds a medical license. Licenses that have been revoked, suspended, are on probation, or are subject to conditions of any type, are considered to be restricted.

4. **Unrestricted Hospital Privileges** While full, unrestricted privileges to perform all CFP procedures are preferred, at a minimum, these privileges must allow the candidate to perform an in-hospital consultation on patients who have been admitted. The candidate’s privileges must remain in effect at the time of the Senior Candidate Examination and may not be suspended or revoked, and the candidate must not be under investigation for patient care issues. Privileges are required as follows:
   
a. CFP Fellowship graduates completing training between July 1, 2021, and September 30, 2022, are required to have hospital privileges at the time of the examination. May collect cases from either fellowship and/or practice.

   b. All other senior candidates must have hospital privileges at the time of application and must collect cases from practice.

   If a candidate does not have hospital privileges, the candidate should contact ABOG at applications@abog.org.

5. **Resignation of Hospital Privileges** A senior candidate must not have resigned hospital privileges or membership in any medical organization (e.g., ACOG) while under investigation. If the candidate is under investigation or on probation, the application will not be approved. The candidate must reapply and pay a new application fee once the probation and/or restrictions have been resolved. However, resolution of these matters does not guarantee that the candidate’s application will be approved.

6. **CFP Practice Focus** A minimum of 30% of the physician’s practice (including inpatient and outpatient) must be limited to patients with CFP diagnoses.

7. **Six-Month Case Log** All senior candidates—including those who have not practiced independently for a minimum of 3 years—will be required to submit a 6-month case log documenting a practice that demonstrates sufficient depth and breadth of practice in the subspecialty of CFP. The case log must be completed at the time of application on the form(s) provided with the online applications. (See Appendix B.)

8. **Moral and Ethical Behavior** The candidate must have demonstrated good moral and ethical behavior in the practice of medicine and in interactions with peers, other medical personnel, and patients. A felony conviction, even if unrelated to the practice of medicine, will be considered evidence of failure to meet this standard.

9. **Falsification of Information** Falsification of any information or failure to disclose any adverse action will result in revocation of a candidate’s eligibility to sit for the Senior Candidate Examination.

10. **International Practice** A candidate who practices outside of the United States, its territories, or Canada, must submit, with the application, a letter(s) from a senior responsible officer in
the hospital(s) where the candidate practices, verifying the candidate’s responsibility for independent, unsupervised care of CFP patients.

Physicians who have made major contributions to the field of CFP but are no longer in full-time practice and cannot submit an adequate case log may request special consideration of the Division of CFP. Such physicians should write a detailed letter of request to the Executive Director of ABOG. The letter must include a summary of their contributions to the field and a copy of their CV. If the request is granted, that physician will be allowed to sit for the CFP Senior Candidate Examination. Once certified, they must enroll in the CFP MOC process.

Physicians who complete an ACGME-accredited CFP fellowship after September 30, 2022, must pass both a qualifying (written) and certifying (oral) examination.

Physicians who finish training in a non-ACGME-accredited fellowship after September 30, 2022, will not be eligible for certification in CFP by ABOG.

More on Case Logs

1. A Case Log must be completed as part of the application process. The form must be completed and submitted online. An example of the proposed form is shown in Appendix B.

2. The deadline for submission of all application materials, including the case log, is March 1, 2024.

3. The numbers reported in the case log may be from any consecutive 6-month period between January 1, 2021, and December 31, 2023.

4. The candidate is not required to perform every procedure included in the case log to be eligible for certification. The candidate should include the total numbers of each procedure for the collection period, and the case log will be used to verify the candidate’s practice has sufficient breadth and depth to be eligible for certification in Complex Family Planning.

Application Process

If you wish to apply and the application is not available on your ABOG portal, please contact applications@abog.org for assistance. Senior candidates who have completed a CFP fellowship before September 30, 2022, and have not practiced for 3 years must have a fellowship affidavit form signed by either the current Fellowship Program Director or the Chair of the Department of Obstetrics and Gynecology. During the application process, a completed Verification of Hospital Privileges Form will be required. This form must be printed from the candidate’s ABOG portal and must be signed and uploaded using the task on the candidate’s ABOG portal dashboard. If a candidate does not have hospital privileges, the candidate should contact ABOG at applications@abog.org.

Applications will be accepted online beginning January 3. Late fees will apply for applications received after February 16. (See table in Deadlines and Fees section). The last day to apply for the CFP Senior Candidate Examination is March 1. The examination fee must be paid in full by credit card at the time of the application. All fees are quoted and must be paid in US dollars.

An approval email will be sent to each applicant at the email address currently listed in the Profile Section of the applicants personal ABOG portal when they are approved to take the CFP Senior
Candidate Examination. Once a candidate is approved to take the examination, any questions about exam protocols and processes should be emailed to exams@abog.org.

After the approval email from ABOG is received, the candidate must contact Pearson VUE to obtain a seat for the examination. Candidates are urged to obtain a seat as soon as possible after notification of eligibility to avoid long-distance travel to a site with an available seat. On April 26, the ABOG reserved seats held at the Pearson VUE centers will be released. After that date, it will be harder for candidates to reserve a seat at their preferred site. Seats in individual cities are limited and are assigned on a first-come, first-served basis. ABOG will not refund any portion of the test fee if a candidate is not able to reserve a seat at their preferred testing center. If special accommodations are needed for a disability, those requests must be received no later than the close of the application period and should be sent to exams@abog.org, before making a reservation at Pearson VUE for information on how to schedule a test site. (See Appendix C for more information about accommodations for disabilities).

Candidates who are lactating may request a 30-minute break and extension of their examination if they notify the ABOG office no later than March 1 and schedule at a Pearson VUE Testing Center by the same date. Pearson VUE Centers have limited lactation facilities which are scheduled on a first-come, first-served basis. If a candidate requests extra time for lactation, they will have to schedule their testing site through the Pearson VUE accommodations department after contacting ABOG. If no seat is available at the closest center, and they have requested extra time, they will have to travel to an available location to sit for the examination. (See Appendix D for more information on lactation accommodations.)

The CFP Senior Candidate Examination will be administered on July 22.

Each year ABOG notifies the American College of Obstetricians and Gynecologists (ACOG), the Society for Family Planning (SFP), the American Board of Medical Specialties (ABMS), the American Medical Association (AMA), and the American Journal of Obstetrics and Gynecology of the names and addresses of the Diplomates who have been certified in the course of that year. ABOG also provides de-identified data to fellowship programs and to the ACGME about fellowship program pass rates to be used as a criterion to evaluate the effectiveness of program training. ABOG, SFP, ACOG, AMA, and ABMS, on request, also make this information available to the public, including, but not limited to, hospitals, agencies of government, insurers, and laypersons. ABOG may use the results of certification examinations for research purposes and may publish the results of the research. As a condition for acceptance as a candidate for certification as a Diplomate in the CFP subspecialty, each candidate, at the time of the Senior Candidate Examination, is required to sign an irrevocable waiver authorizing the dissemination of the candidate’s certification status without limitation or condition.

Applicants Ruled Not Admissible

If a decision is made by ABOG that a senior candidate has not met the requirements for admission to the Senior Candidate Examination, the candidate may appeal the decision by writing to applications@abog.org. Such appeals will be forwarded to the appropriate ABOG Committee for reconsideration. If the appeal is successful, no late fees will apply. If the successful decision occurs after the date of the Senior Candidate Examination, the candidate will be scheduled for the next available Senior Candidate Examination in the subspecialty, and no additional application fee will apply. However, the examination portion of the fee ($870) must be paid before the deadline.
If the candidate’s appeal is not successful or the candidate does not appeal the inadmissibility decision, the candidate may reapply by submitting a new application, paying the appropriate fee, and meeting the requirements applicable at the time of the reapplication. Documentation that the cause for the initial disapproval has been cleared must be submitted with the application.

**Deadlines and Fees**

The fee for the CFP Senior Candidate Examination is $2045 and must be paid in full at the time of application. The fee has been computed to cover the costs of the examination and administrative expenses. Fees will not be credited towards future examination applications. All applications and fees must be submitted on the candidate’s ABOG portal prior to midnight Central time on their due date. The system will prevent submission once the deadline has passed. The total fee (application and examination) must be paid by credit card through the candidate’s ABOG portal and is payable in US Dollars only.

After approval, if the candidate experiences an event that prevents sitting for the examination, the Board should be notified immediately. If the ABOG review committee determines that the request is due to circumstances beyond the control of the candidate, the examination portion of the fee ($870) may be refunded. However, the application fee is not refundable.

**2024 CFP Senior Candidate Examination Deadlines**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 3</td>
<td>Applications available online</td>
</tr>
<tr>
<td>February 16</td>
<td>Last day to apply without late fee penalty</td>
</tr>
<tr>
<td>March 1</td>
<td>Final deadline</td>
</tr>
<tr>
<td>January to March</td>
<td>Candidates will be notified of approval to take the examination and to make a Pearson VUE Testing Center reservation</td>
</tr>
<tr>
<td>April 26</td>
<td>Last day to reserve a seat at Pearson VUE prior to seat block release</td>
</tr>
<tr>
<td>July 22</td>
<td>Senior Candidate Examination at testing centers</td>
</tr>
</tbody>
</table>

**2024 CFP Senior Candidate Examination Fees**

<table>
<thead>
<tr>
<th>Date Range</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 3 to February 16</td>
<td>$2045</td>
</tr>
<tr>
<td>February 17 to March 1</td>
<td>$2045 + $320 late fee = $2365</td>
</tr>
</tbody>
</table>

**Administration of the Senior Candidate Examination**

The Senior Candidate Examination is scheduled to last approximately 3 hours and 45 minutes. Candidates who finish before the full time has elapsed may leave early, but if they do so, they...
may not return. Candidates will receive information after registering on the Pearson VUE Testing Center website concerning the location of their examination, as well as the time they must arrive.

Each candidate must present 2 forms of identification to be admitted to the examination. One document must include both a photograph of the candidate and the candidate’s signature. The second document must include the candidate’s signature. If a candidate has had a name change between application and the day of the exam, they must bring a copy of an official document that verifies the name change. Examples could include but are not limited to a marriage certificate, divorce decree, or a court-ordered name change.

Candidates may not take any electronic devices into the examination area and must also submit to a screening process that may include any or all of the following: fingerprinting, palm vein scanning, wanding or walkthrough scanning for metallic objects, or any other screening that may be in place at the Pearson VUE center. A candidate who refuses to submit to any screening procedure will not be allowed to sit for the examination, and no portion of the fee will be refunded.

Candidates are not allowed to access recording devices, cellular phones, paging devices, smartwatches, other electronic communication and/or recording devices, or writing instruments during the Senior Candidate Examination. If such a device is discovered on the candidate's person at any time during the examination, or if the candidate accesses any such device for any reason, the candidate will not receive a grade for any portion of the examination, and all fees will be forfeit. The only exceptions are medically required devices, such as an insulin pump.

There is no scheduled break during the examination. Candidates may take unscheduled breaks to use the restroom facilities. Unscheduled breaks should not exceed ten minutes in length. During such breaks, a candidate may not talk with any other individual or access any electronic device. Candidates are not allowed to leave the testing center for any reason before completing the test. If a candidate violates any of these regulations, the candidate will not receive a grade for any portion of the examination, and all fees will be forfeit.

**Test Security**

At the time of application for the Senior Candidate Examination, each candidate will be required to agree to the following. No candidate will be allowed to sit for the Senior Candidate Examination unless they agree to these terms:

1. I understand that all ABOG test materials are copyrighted and that it is illegal to disclose the content of the examination in whole or in part to any individual, organization, or business. Furthermore, I understand that if I provide the information to any such entity, I may be prosecuted under the US Copyright laws.

2. I understand that if I divulge the content of the Senior Candidate Examination in whole or in part to any individual, organization, or business, my test result, if any, will be negated, and I will not be allowed to reapply for the Senior Candidate Examination for a minimum of three (3) years.

3. I understand that I may not record any portion of the Senior Candidate Examination by any means in whole or in part, and a violation will be treated as outlined in numbers 1 and 2 above.
4. I understand that I may not memorize or attempt to memorize any portion of the Senior Candidate Examination for the purpose of transmitting such material to any individual, organization, or business.

5. I agree that de-identified results of my examination may be used for research purposes by ABOG.

6. If I graduated from a CFP fellowship program, I agree that the results of my examination will be given to my Fellowship Program Director.

Additional information about test integrity and security can be found under the “Policies” tab on the ABOG website.

Senior Candidate Examination Content

The candidate will be expected to demonstrate skills necessary to apply the appropriate knowledge to the management of clinical problems. These skills include:

1. obtaining needed information;
2. interpretation and use of data obtained;
3. selection, instituting, and implementing appropriate care;
4. management of complications; and
5. follow-up and continuing care.

The examination consists of 230 single-best answer, multiple-choice questions. Many of the questions are constructed to be thought-provoking and problem-solving. For most questions, all possible answers may be plausible, but only one answer is the most correct. The CFP Senior Candidate Examination will only be given in English.

The content of the Senior Candidate Examination will be based on the blueprint for Complex Family Planning. The major categories and subcategories are shown below, including the percentages of the categories.

Contraception (35%)

- Provide contraceptive counseling, provision, and surveillance to patients and contraceptive consultation to other health care providers
- Demonstrate advanced knowledge of pharmacology (mechanism of action, dosing, route of administration/absorption, contraindications, metabolism, excretion), effectiveness, potential side effects, and complications of all contraceptive methods
- Provide care for patients with specialized contraceptive needs (e.g., limited access or medical considerations)
- Provide contraceptive counseling, provision, and surveillance for patients with pre-existing medical or anatomical conditions
- Evaluate and manage side effects related to contraception
- Evaluate and manage complications related to contraception
- Evaluate and manage complicated contraceptive removals, including malpositioned or broken devices, with the use of imaging if needed
Early Pregnancy Evaluation and Management (15%)
   Evaluate early pregnancy
   Manage early pregnancy
   Manage and surveil gestational trophoblastic disease with other subspecialties

Abortion / Pregnancy Termination (40%)
   Provide comprehensive counseling to patients about abortion and consultation to other health care providers
   Provide abortion counseling for patients with special reproductive needs
   Perform a pre-abortion evaluation
   Provide medication abortion
   Perform procedural abortion
   Evaluate, diagnose, and manage abortion complications

Research, Health Policy, and Advocacy (5%)
   Research
   Public Health and Reproductive Health Policy
   Advocacy

Core Competencies and Cross Content (5%)
   Ethics and Professionalism
   Patient Safety
   Interpersonal and Communication Skills
   Systems-based Practice
   Practice-based Learning and Improvement
   Evidence-based Medicine

The specific topics covered in these areas can be found in Appendix E.

All approved abbreviations on ABOG examinations can be found in Appendix F.

Results and Scoring

The results of the CFP Senior Candidate Examination will be reported online to each candidate on or before the last Friday in October. We recognize waiting close to 12 weeks for these important results is difficult and the format of the examination, multiple choice and computer administered, creates an expectation for immediate feedback. Please be assured during this post-examination period, extensive quality assurance checks take place to ensure your test result is fair and accurate. For example, content on the CFP Senior Candidate Exam is re-reviewed to identify potentially flawed questions. If ABOG determines a question with more than
one correct answer (or no correct answer) was on the CFP Senior Candidate Exam, test-takers will not be penalized for that item.

When results are released, ABOG will provide the candidate their scaled test score in addition to the result of “pass” or “fail.” Each candidate, regardless of whether they pass or fail, will be provided with the percent scored in each of the major topic areas. The cut-point for passing the CFP Senior Candidate Examination is determined using standard setting methodology every 3-5 years and is equated statistically between that time.

As part of the application process, the applicant will be required to irrevocably agree that the results of the applicant’s examination may be made available to the Program Director(s) of any fellowship program(s) in which the applicant may have participated or in which the applicant is currently involved, and/or the American Council of Graduate Medical Education (ACGME) for any and all purposes. The candidate will also be given the opportunity to release their scaled score on the examination to their current Program Director. Furthermore, the applicant will be required to release and agree to indemnify and hold ABOG and its officers, directors, and employees harmless of and from any and all claims the applicant may have with regard to the effect or impact upon the applicant of the release of the applicant’s examination results to the applicant’s Program Director or the ACGME and waive any rights the applicant may have, if any, to have the examination results maintained in confidence.

Rescores and Appeals

Since ABOG utilizes many quality control procedures to ensure exams are scored accurately and there is no record of incorrect scoring at ABOG with any of ABOG’s Qualifying Examinations or the CFP Senior Candidate Examinations, ABOG does not accept rescore requests. This includes, but is not limited to, rescoring of the exam, review of exam content, reconsideration of a correct response, reconsideration of the passing standard, and/or consideration of the acceptability of testing conditions.

In addition, ABOG does not accept appeals from candidates who seek to challenge the content of the examination, the sufficiency or accuracy of the answers to examination questions, the scoring of the examination, or the cut score used to determine the passing grade for the examination.

A complaint concerning any other matter of the CFP Senior Candidate Examination should be sent to exams@abog.org.

Requests for Re-Examination

Candidates who are scheduled to take the CFP Senior Candidate Examination but do not do so, as well as candidates who do not pass the examination and who wish to repeat the examination, must complete a new application on the ABOG website and pay a new fee. The last such exam will be given in July 2025.

Length of Certification

All certificates issued by ABOG after 2008 are time-limited. The certification of a Diplomate who successfully passes the Complex Family Planning Senior Candidate Examination in July 2024 will expire on December 31, 2025, unless all of the 2025 MOC assignments have been
successfully completed. Applications for the 2025 MOC process will be available online beginning in January 2025.

CERTIFYING (ORAL) EXAMINATION

There is no oral examination requirement for CFP senior candidates.

APPENDIX A: ABOG DIVISION OF COMPLEX FAMILY PLANNING

Courtney Schreiber, MD, MPH, **Division Chair**  Perelman School of Medicine at University of Pennsylvania

Amy (Meg) Autry, MD  University of California, San Francisco, School of Medicine

Eve Espey, MD, MPH  University of New Mexico School of Medicine

Sadia Haider, MD, MPH  Rush Medical College of Rush University

Biftu Mengesha, MD, MAS  University of California, San Francisco, School of Medicine

Gretchen Stuart, MD, MPH  University of North Carolina School of Medicine

Stephanie Teal, MD, MPH  Case Western Reserve University School of Medicine-University Hospitals
APPENDIX B: CASE LOG

Candidates for the CFP Senior Candidate Examination must submit a case log. The log must document that a minimum of 30% of the physician’s practice involves Complex Family Planning. A draft example of the case log follows. The actual case log may differ from this example. Candidates should use the case log given at the time of application. Candidates will be asked to submit the case log at the time of application and attest that 30% or more of their practice involves caring for patients with complex family planning problems.
Six-Month Case Log for Senior CFP Candidates

[SAMPLE: DO NOT use the list below. The actual case log will open at the time of application and may contain different categories and/or minimum numbers of cases from those shown in this appendix.]

Please complete the following form listing all patients you have treated during the 6-month period of time you indicate below.

Name: ________________________________  ABOG ID#: ____________

Beginning Date: ______________________

End Date: ____________________________

A. Outpatient Visits – New/Consult Patients only
   Enter the total number of new patients seen by you in your practice during the six-month period shown above.

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>All contraceptive visits</td>
<td></td>
</tr>
<tr>
<td>Contraceptive complications</td>
<td></td>
</tr>
<tr>
<td>Contraceptives in medically complex patients</td>
<td></td>
</tr>
</tbody>
</table>

B. Abortion/Pregnancy Termination

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>New patient for abortion counseling</td>
<td></td>
</tr>
<tr>
<td>Medication Abortion</td>
<td></td>
</tr>
<tr>
<td>First Trimester Procedural Abortion</td>
<td></td>
</tr>
<tr>
<td>Second Trimester Procedural Abortion</td>
<td></td>
</tr>
<tr>
<td>Management of Abortion Complications</td>
<td></td>
</tr>
</tbody>
</table>

C. Other Procedures
   (Include both inpatients and outpatients.)

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transvaginal Ultrasound</td>
<td></td>
</tr>
<tr>
<td>Contraceptive placements</td>
<td></td>
</tr>
<tr>
<td>Contraceptive removals</td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX C: CANDIDATE DISABILITY

The American Board of Obstetrics & Gynecology, Inc. (ABOG) provides reasonable accommodations in accordance with The Americans with Disabilities Act (ADA) as amended by the ADA Amendments Act of 2013 (ADAAA) (collectively the ADA) and, therefore, will provide or allow the use of necessary auxiliary aids, services, or testing conditions that do not fundamentally alter the measurement of the skills or knowledge the Board assessment program and examination is intended to test. Candidates must indicate through the examination application if special testing accommodations under the ADA are needed.

The ADA defines a person with a disability as someone with a physical or mental impairment that substantially limits one or more major life activities such as walking, standing, seeing, hearing, eating, sleeping, speaking, breathing, learning, reading, concentrating, thinking, communicating, or working.

The purpose of accommodations is to provide equal access to ABOG examinations for all individuals. Accommodations offset the identified functional limitation so that the impact of impairment is minimized by means of an auxiliary aid or an adjustment to the testing procedure. Functional limitation refers to the aspects of a disability that interfere with an individual’s ability to function in some capacity on a regular and continuing basis.

Accommodations for the Senior Candidate Examination will only be considered with appropriate documentation. Documentation should be provided no later than the close of the application period to permit ABOG to verify the existence, nature, and extent of the disability. The documentation must specify the requirements or accommodations determined to be necessary to overcome or compensate for the disability. In addition, the candidate must supply any additional information ABOG may subsequently request in a timely manner. If any of the requirements or accommodations cannot reasonably be provided, ABOG will notify the candidate and will indicate those alternative accommodations which ABOG determines to be appropriate in consideration of the disability claimed and documented and the integrity of the examination. If the candidate fails to notify ABOG of a disability during the application period and fails to achieve a passing grade, that candidate may not appeal the results of the examination but shall be entitled to sit for the next regularly scheduled examination but must pay a new application and examination fee.

If a candidate claims that their examination results were adversely affected by illness, injury, or other temporary physical impairment at the time of the examination, that candidate may not appeal the results of the examination. However, if the candidate provides sufficient evidence of such illness, injury, or impairment, they shall be entitled to sit for the next regularly scheduled examination but must pay a new application and examination fee.

ABOG shall not exclude any candidate from the Senior Candidate Examination solely because of a disability if ABOG is provided with notice of the disability in time to permit ABOG to make such adjustments in the examination as are reasonably necessary to accommodate the disability.
APPENDIX D: LACTATION ACCOMMODATIONS

Candidates who are lactating may request a 30-minute break and extension of their examination if they notify the ABOG office no later than March 1, 2024, and schedule at a Pearson VUE Testing Center by the same date. Most Pearson VUE Testing Centers have only one room available for breast pumping, so candidates are encouraged to make their reservations as soon as they receive approval for the test as these rooms will be assigned on a first-come, first-served basis. If a candidate requests extra time for lactation, they must schedule their testing site through the Pearson VUE accommodations department after contacting ABOG. If no seat is available at the closest center, and they have requested extra time, they will have to travel to an available location to sit for the examination. As Pearson VUE testing centers have limited lactation facilities, ABOG cannot guarantee that the candidate will be able to schedule at their preferred testing center.
APPENDIX E: CFP SENIOR CANDIDATE EXAMINATION TOPICS

Contraception

1. Provide contraceptive counseling, provision, and surveillance to patients and contraceptive consultation to other health care providers
   a. Engage in person-centered counseling to identify reproductive life goals
   b. Screen patients for contraceptive coercion
   c. Implement practices to improve access to contraception (e.g., same-day IUD insertion, quick start)

2. Demonstrate advanced knowledge of pharmacology (mechanism of action, dosing, route of administration/absorption, contraindications, metabolism, excretion), effectiveness, potential side effects, and complications of all contraceptive methods
   a. Coitally-dependent
   b. Short-acting
   c. Long-acting
   d. Permanent
   e. Emergency contraception

3. Provide care for patients with specialized contraceptive needs (e.g., limited access or medical considerations)
   a. Adolescent patients
   b. Perimenopausal patients
   c. LGBTQIA patients
   d. Patients with substance and alcohol use disorder
   e. Patients with disabilities
   f. Patients experiencing intimate partner violence and sexual assault
   g. Patients who are incarcerated
   h. Postpartum or post-abortion patients (including immediate LARC)

4. Provide contraceptive counseling, provision, and surveillance for patients with pre-existing medical or anatomical conditions
   a. Evaluate and manage interactions between contraception and medications
   b. Evaluate and manage interaction between medical conditions and contraception (e.g., HIV infection, renal disease, hepatic disease, hematologic disorders, thromboembolic disorders, cardiac disease, mental health disorders, connective tissue disorders, STIs, PID)
   c. Provide care for patients with reproductive tract anomalies (e.g., uterine anomalies, leiomyomata)
d. Perform complex placement of contraceptive devices [e.g., patients with anatomic challenges (e.g., stenotic cervix, leiomyomata, reproductive tract anomalies) or physical or mental conditions impacting insertion (e.g., contractures, developmental delay)]

e. Utilize contraception for non-contraceptive benefits (e.g., management of uterine bleeding, catamenial seizures, perimenopausal)

5. Evaluate and manage side effects related to contraception
   a. Evaluate reported side effect(s) with respect for patient autonomy (e.g., modeling non-coercive practice)
   b. Counsel patients about alternative methods of contraception based on side effect history
   c. Offer management options for method side effects

6. Evaluate and manage complications related to contraception
   a. Identify severe adverse complications and refer for management (e.g., stroke, DVT, myocardial infarction)
   b. Evaluate and manage if intrauterine pregnancy occurs with contraceptive methods

7. Evaluate and manage complicated contraceptive removals, including malpositioned or broken devices, with use of imaging if needed
   a. IUD (e.g., missing strings, embedded, uterine perforation)
   b. Implants (e.g., nonpalpable implants, broken devices)
   c. Use of hysteroscopy and laparoscopy for removal of devices
   d. Determine when additional expertise and/or facilities are needed (e.g., interventional radiology, other surgical specialties, and specialty laboratories)

**Early Pregnancy Evaluation and Management**

1. Evaluate early pregnancy
   a. Determine pregnancy location (e.g., intrauterine, extrauterine, cesarean scar, cervical, cornual)
   b. Evaluate intrauterine pregnancy (e.g., evolution of ultrasonographic landmarks, gestational age, etc.)
   c. Demonstrate knowledge of ectopic risk factors (e.g., IUD in situ, prior tubal ligation, prior ectopic)

2. Manage early pregnancy
   a. Provide pregnancy options counseling
   b. Provide counseling about options for management of pregnancy of unknown location (PUL), early pregnancy loss (EPL), and ectopic pregnancy (e.g., intrasac injections, laparoscopy, uterine aspiration, multi-modal approach)
   c. Use uterine aspiration for diagnosis and treatment of PUL and EPL
   d. Use of mifepristone and/or misoprostol for PUL
e. Use of mifepristone and/or misoprostol for EPL

3. Manage and surveil gestational trophoblastic disease with other subspecialties
   a. Procedurally manage gestational trophoblastic disease (e.g., second-trimester uterine evacuation)
   b. Identify the consequences of gestational trophoblastic disease (e.g., thyroid storm and hypertension)
   c. Provide counseling for and manage contraception after treatment of gestational trophoblastic disease
   d. Diagnose gestational trophoblastic disease and refer patients

**Abortion/Pregnancy Termination**

1. Provide comprehensive counseling to patients about abortion and consultation to other health care providers
   a. Provide comprehensive options counseling to patients
   b. Screen patients for interpersonal reproductive coercion
   c. Facilitate identification of patient-led reproductive goals (e.g., post-abortion contraception, general contraception, reproductive life planning)
   d. Incorporate comprehensive knowledge of local laws and regulations into counseling
   e. Describe methods of abortion to patients (e.g., medication, procedure, induction, feticidal injection, third-trimester options)

2. Provide abortion counseling for patients with special reproductive needs
   a. Adolescent patients
   b. LGBTQIA patients
   c. Patients with substance and/or alcohol use disorder
   d. Patients experiencing intimate partner violence and/or sexual assault
   e. Patients who are incarcerated
   f. Patients with disabilities

3. Perform a pre-abortion evaluation
   a. Identify patients at risk for abortion complications (e.g., prior uterine surgery, uterine anomalies, cervical anomalies)
   b. Identify comorbidities that influence abortion care (e.g., cardiac disease, seizure disorders, renal disorders, coagulopathies, fetal demise)
   c. Evaluate the results of laboratory studies (e.g., Rh typing, CBC, CMP)
   d. Perform ultrasound as needed (e.g., to determine pregnancy location, determine gestational age, diagnose uterine anomalies, diagnose multiple gestations, identify placental location, and recognize signs of abnormal placentation)
   e. Determine the need for additional imaging studies (e.g., MRI, CT scan, ultrasound)
f. Determine the need for consultations from other health care specialties (e.g., hematology, cardiology, anesthesiology)

g. Determine appropriate location for completion of abortion (e.g., at home, free-standing clinic, hospital-based clinic, operating room) based on patient risk factors (e.g., gestational age, comorbidities, fetal demise)

h. Determine options for abortion method including feticidal injections

i. Counsel patients on available genetic testing options

j. Determine need for peri-abortal medications (e.g., Rh immunoglobulin, antibiotics, antiemetics, uterotonics)

k. Provide a multi-modal plan for pain management during and after an abortion

4. Provide medication abortion

a. Demonstrate advanced knowledge of pharmacology (mechanism of action, dosing, route of administration/absorption, contraindications, metabolism, excretion) for medication abortion at various gestational ages (e.g., mifepristone, misoprostol, methotrexate, oxytocin)

b. Counsel regarding risks and benefits of treatment regimen for medication abortion at any gestational age

c. Determine medication regimen based on patient factors (e.g., gestational age, prior uterine scar)

d. Surveil patients to assess abortion completion (e.g., laboratory, ultrasound, clinical)

e. Provide complex labor inductions for second and/or third-trimester abortion (e.g., history of cesarean deliveries, leiomyomatous uterus, prolonged induction)

5. Perform procedural abortion

a. Perform abortions for patients with comorbidities (e.g., prior surgery, fibroids, vascular malformations, multi-gestation, emergent uterine evacuation)

b. Provide cervical preparation to patients, including those with comorbidities (e.g., cervical anomalies, previous uterine surgery, advanced gestational age, urgent uterine evacuation)

c. Provide pain management and/or anesthesia (e.g., paracervical block, sedation, non-pharmacological pain management)

d. Utilize ultrasound guidance during procedural abortion

e. Perform abortion via electric or manual uterine aspiration

f. Perform abortion via dilation and evacuation

g. Perform abortion via dilation and extraction

h. Assess for abortion completion (e.g., tissue examination, laboratory studies, ultrasound)

6. Evaluate, diagnose, and manage abortion complications

a. Hemorrhage

b. Retained products of conception
c. Hematometra
d. Uterine perforation and initial management of resulting injuries (e.g., genitourinary, gastrointestinal, vascular)
e. Cervical lacerations
f. Amniotic fluid embolism (AFE)
g. Thrombotic event
h. Anesthesia complications
i. Undiagnosed placenta site abnormalities
j. Infection
k. Septic abortion
l. Heterotopic pregnancy (initially manage)
m. Vasovagal response
n. Continuing pregnancy after abortion
o. Unplanned delivery prior to scheduled procedure
p. Disseminated intravascular coagulopathy
q. Uterine rupture

Research, Health Policy, and Advocacy

1. Research
   a. Demonstrate knowledge of basic research methodology (e.g., study design, sample size)
   b. Critically analyze published studies
   c. Determine the proper biostatistical test based on data type and study questions
   d. Demonstrate knowledge of research ethics (e.g., informed consent, vulnerable populations)

2. Public Health and Reproductive Health Policy
   a. Understand how reproductive health impacts public health and health policy
   b. Identify disparities in reproductive health, including access, care quality, patient experience, and outcomes
   c. Identify professional organizations that advocate for and influence policy in reproductive health
   d. Demonstrate knowledge of social and structural determinants that create reproductive health inequities in marginalized groups

3. Advocacy
   a. Engage with stakeholders (e.g., public, other healthcare providers, policymakers) about the role of family planning in public health and health policy
b. Engage with the work of professional organizations that advocate for health policy in contraception and abortion

c. Demonstrate the knowledge and skills to advocate for equitable access to reproductive health services

**Core Competencies and Cross Content**

1. Ethics and Professionalism
   a. Systematically engage in practice review to identify health disparities
   b. When engaged in shared clinical decision making, incorporate patient, family, and cultural considerations in making treatment recommendations
   c. When providing care for patients, consider psychological, sexual, and social implications of various treatment options

2. Patient Safety
   a. Systematically analyze the practice for safety improvements (e.g., root cause analysis)
   b. Systematically engage in practice reviews for safety improvements (e.g., root cause analysis)
   c. Incorporate the standard use of procedural briefings, “time outs,” and debriefings in clinical practice
   d. Participate in the review of sentinel events, reportable events, and near misses
   e. Implement universal protocols (e.g., bundles, checklists) to help ensure patient safety

3. Interpersonal and Communication Skills
   a. Communicate to patient and family regarding adverse outcomes and medical errors
   b. Demonstrate sensitivity and responsiveness when communicating with a diverse patient population, including but not limited to diversity in gender, age, culture, race, religion, disabilities, and sexual orientation
   c. Provide comprehensive information when referring patients to other professionals

4. Systems-based Practice
   a. Incorporate considerations of cost awareness and risk-benefit analysis in patient care
   b. Provide care with multidisciplinary teams to promote patient safety and optimize patient outcomes

5. Practice-based Learning and Improvement
   a. Design or participate in practice or hospital quality improvement activities

6. Evidence-based Medicine
   a. Incorporate evidence-based practices and national guidelines to improve practice patterns and outcomes
   b. Implement evidence-based protocols to enhance recovery after surgery (ERAS)
APPENDIX F: APPROVED ABBREVIATIONS FOR ABOG EXAMINATIONS

2D 2-dimensional
3D 3-dimensional
17-OHP 17-hydroxyprogesterone
aCGH Array comparative genomic hybridization
ACTH Adrenocorticotropic hormone
AFI Amniotic fluid index
AFP Alpha-fetoprotein
AGC Atypical glandular cells
AIS Adenocarcinoma in situ
ALT Alanine aminotransaminase
AMA Advanced maternal age
AMH Antimullerian hormone
ANC Absolute neutrophil count
APS Antiphospholipid antibody syndrome
ARDS Acute respiratory distress syndrome
AROM Artificial rupture of membranes
ART Antiretroviral therapy or Assisted reproductive technology
ASA score American Society of Anesthesiologists score
ASC Abdominal sacrocolpopexy
ASCUS Atypical cells of undetermined significance
ASRM American Society for Reproductive Medicine
AST Aspartate aminotransaminase
ATFP Arcus tendineus fascia pelvis
AUB Abnormal uterine bleeding
AZF Azoospermia factor
BEP Bleomycin, etoposide, cisplatin
BSO Bilateral salpingo-oophorectomy
BTL Bilateral tubal ligation
BMI Body mass index
BUN Blood urea nitrogen
Cm Centimeter
CA125 Cancer antigen 125
CBAVD Congenital bilateral absence of the vas deferens
CBC Complete blood count
CD4 Cluster of differentiation 4
CEA Carcinoembryonic antigen
CI Confidence interval
CIN Cervical intraepithelial neoplasia
CMV Cytomegalovirus
CNS Central nervous system
COC Combined oral contraceptive
CPR Cardiopulmonary resuscitation
CT Computerized tomography
CTA Computerized tomography angiography
CTLA-4 Cytotoxic T lymphocyte-associated antigen 4
CVS Chorionic villus sampling
dMMR Deficient mismatch repair
D & C Dilatation and curettage
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D &amp; E</td>
<td>Dilatation and evacuation</td>
</tr>
<tr>
<td>DEXA</td>
<td>Dual-energy x-ray absorptiometry</td>
</tr>
<tr>
<td>DHEA</td>
<td>Dehydroepiandrosterone</td>
</tr>
<tr>
<td>DHEAS</td>
<td>Dehydroepiandrosterone sulfate</td>
</tr>
<tr>
<td>DIC</td>
<td>Disseminated intravascular coagulopathy</td>
</tr>
<tr>
<td>DKA</td>
<td>Diabetic ketoacidosis</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DSD</td>
<td>Differences of sexual development</td>
</tr>
<tr>
<td>DVT</td>
<td>Deep vein thrombosis</td>
</tr>
<tr>
<td>EAS</td>
<td>External anal sphincter</td>
</tr>
<tr>
<td>EBL</td>
<td>Estimated blood loss</td>
</tr>
<tr>
<td>ECC</td>
<td>Endocervical curettage</td>
</tr>
<tr>
<td>ECMO</td>
<td>Extracorporeal membrane oxygenation</td>
</tr>
<tr>
<td>EGA</td>
<td>Estimated gestational age</td>
</tr>
<tr>
<td>EIN</td>
<td>Endometrial intraepithelial neoplasia</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EKG/ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>EMA-CO</td>
<td>Etoposide, methotrexate, actinomycin D-cyclophosphamide, Oncovin®</td>
</tr>
<tr>
<td>EMB</td>
<td>Endometrial biopsy</td>
</tr>
<tr>
<td>EFW</td>
<td>Estimated fetal weight</td>
</tr>
<tr>
<td>ER</td>
<td>Estrogen receptor</td>
</tr>
<tr>
<td>ERAS</td>
<td>Enhanced recovery after surgery</td>
</tr>
<tr>
<td>ESHRE</td>
<td>European Society of Human Reproduction and Embryology</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FENa</td>
<td>Fractional excretion of sodium</td>
</tr>
<tr>
<td>FFP</td>
<td>Fresh frozen plasma</td>
</tr>
<tr>
<td>FGR</td>
<td>Fetal growth restriction</td>
</tr>
<tr>
<td>FHR</td>
<td>Fetal heart rate</td>
</tr>
<tr>
<td>FHT</td>
<td>Fetal heart tones</td>
</tr>
<tr>
<td>FIGO</td>
<td>International Federation of Gynecology and Obstetrics</td>
</tr>
<tr>
<td>FISH</td>
<td>Fluorescence in situ hybridization</td>
</tr>
<tr>
<td>FSH</td>
<td>Follicle-stimulating hormone</td>
</tr>
<tr>
<td>g</td>
<td>Gram</td>
</tr>
<tr>
<td>GBS</td>
<td>Group B streptococcus</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational diabetes mellitus</td>
</tr>
<tr>
<td>GIFT</td>
<td>Gamete intrafallopian transfer</td>
</tr>
<tr>
<td>GnRH</td>
<td>Gonadotropin-releasing hormone</td>
</tr>
<tr>
<td>GOG</td>
<td>Gynecologic Oncology Group</td>
</tr>
<tr>
<td>GTD</td>
<td>Gestational trophoblastic disease</td>
</tr>
<tr>
<td>GTN</td>
<td>Gestational trophoblastic neoplasia</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Hemoglobin A1c</td>
</tr>
<tr>
<td>HELLP</td>
<td>Hemolysis, elevated liver function tests, low platelet count</td>
</tr>
<tr>
<td>HCG</td>
<td>Human chorionic gonadotropin</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>hMG</td>
<td>Human menopausal gonadotropin</td>
</tr>
<tr>
<td>HNPCC</td>
<td>Hereditary nonpolyposis colorectal cancer</td>
</tr>
<tr>
<td>HPO</td>
<td>Hypothalamic-pituitary-ovarian</td>
</tr>
<tr>
<td>HPV</td>
<td>Human papillomavirus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HRT</td>
<td>Hormone replacement therapy</td>
</tr>
<tr>
<td>HSG</td>
<td>Hysterosalpingogram</td>
</tr>
<tr>
<td>HSIL</td>
<td>High-grade squamous intraepithelial lesion</td>
</tr>
<tr>
<td>HSV</td>
<td>Herpes simplex virus</td>
</tr>
<tr>
<td>IAS</td>
<td>Internal anal sphincter</td>
</tr>
<tr>
<td>IC/BPS</td>
<td>Interstitial cystitis/Bladder pain syndrome</td>
</tr>
<tr>
<td>ICSI</td>
<td>Intracytoplasmic sperm injection</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>IgM</td>
<td>Immunoglobulin M</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IPG</td>
<td>Implantable pulse generator</td>
</tr>
<tr>
<td>IUD</td>
<td>Intrauterine device</td>
</tr>
<tr>
<td>IUFD</td>
<td>Intrauterine fetal death</td>
</tr>
<tr>
<td>IUI</td>
<td>Intrauterine insemination</td>
</tr>
<tr>
<td>IUP</td>
<td>Intrauterine pregnancy</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IVF</td>
<td>In vitro fertilization</td>
</tr>
<tr>
<td>IVIG</td>
<td>Intravenous immunoglobulin</td>
</tr>
<tr>
<td>kg</td>
<td>Kilogram</td>
</tr>
<tr>
<td>KUB</td>
<td>Kidney, ureter, bladder</td>
</tr>
<tr>
<td>L &amp; D</td>
<td>Labor and delivery</td>
</tr>
<tr>
<td>LARC</td>
<td>Long-acting reversible contraception</td>
</tr>
<tr>
<td>LAVH</td>
<td>Laparoscopic-assisted vaginal hysterectomy</td>
</tr>
<tr>
<td>LDH</td>
<td>Lactate dehydrogenase</td>
</tr>
<tr>
<td>LEEP</td>
<td>Loop electrosurgical excision procedure</td>
</tr>
<tr>
<td>LGA</td>
<td>Large for gestational age</td>
</tr>
<tr>
<td>LGBTQIA</td>
<td>Lesbian gay bisexual transgender queer intersex asexual</td>
</tr>
<tr>
<td>LFT</td>
<td>Liver function test</td>
</tr>
<tr>
<td>LH</td>
<td>Luteinizing hormone</td>
</tr>
<tr>
<td>LMP</td>
<td>Last menstrual period</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low-molecular-weight heparin</td>
</tr>
<tr>
<td>LSIL</td>
<td>Low-grade squamous intraepithelial lesion</td>
</tr>
<tr>
<td>LVSI</td>
<td>Lymphovascular space invasion</td>
</tr>
<tr>
<td>mL</td>
<td>Milliliter</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mammalian target of rapamycin</td>
</tr>
<tr>
<td>MCA</td>
<td>Middle cerebral artery</td>
</tr>
<tr>
<td>MESA</td>
<td>Microsurgical epididymal sperm aspiration</td>
</tr>
<tr>
<td>MIS</td>
<td>Minimally invasive surgery</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MRKH</td>
<td>Mayer-Rokitansky-Küster-Hauser</td>
</tr>
<tr>
<td>MSAFP</td>
<td>Maternal serum alpha-fetoprotein</td>
</tr>
<tr>
<td>MSI-H, -L</td>
<td>Microsatellite instability-high, -low</td>
</tr>
<tr>
<td>MTP</td>
<td>Massive transfusion protocol</td>
</tr>
<tr>
<td>MURCS</td>
<td>Müllerian duct aplasia, renal aplasia, cervicothoracic somite dysplasia</td>
</tr>
<tr>
<td>NAAT</td>
<td>Nucleic-acid amplification test</td>
</tr>
<tr>
<td>NGS</td>
<td>Next-generation sequencing</td>
</tr>
<tr>
<td>NICU</td>
<td>Neonatal intensive care unit</td>
</tr>
<tr>
<td>NIPT</td>
<td>Noninvasive prenatal testing</td>
</tr>
<tr>
<td>NPO</td>
<td>Nil per os</td>
</tr>
<tr>
<td>NSAID</td>
<td>Nonsteroidal anti-inflammatory drug</td>
</tr>
</tbody>
</table>
OAB  Overactive bladder  
OASIS  Obstetric anal sphincter injuries  
OHSS  Ovarian hyperstimulation syndrome  
OHVIRA  Obstructed hemivagina ipsilateral renal agenesis  
PACU  Postanesthesia care unit  
PALND  Para-aortic lymph node dissection  
PAP  Papanicolaou smear  
PARP  Poly adenosine diphosphate-ribose polymerase  
PCOS  Polycystic ovarian syndrome  
PCR  Polymerase chain reaction  
PD-1  Programmed cell death protein 1  
PD-L1  Programmed cell death ligand 1  
PESA  Percutaneous epididymal sperm aspiration  
PET  Positron emission tomography  
PFMT  Pelvic floor muscle therapy  
PFPT  Pelvic floor physical therapy  
PGT-A  Preimplantation genetic testing for aneuploidy  
PGT-M  Preimplantation genetic testing for monogenic disorder  
PGT-SR  Preimplantation genetic testing for structural rearrangements  
PLND  Pelvic lymph node dissection  
PNE  Peripheral nerve evaluation  
POP  Pelvic organ prolapse  
POP-Q  Pelvic organ prolapse quantification system  
PPH  Postpartum hemorrhage  
PR  Progesterone receptor  
PROM  Premature rupture of membranes  
PT  Prothrombin time  
PTT  Partial thromboplastin time  
PPROM  Preterm premature rupture of membranes  
PTNS  Posterior tibial nerve stimulation  
PUBS  Percutaneous umbilical blood sampling  
PUPPP  Pruritic urticarial papules and plaques of pregnancy  
PVR  Postvoid residual  
RAIR  Rectoanal inhibitory reflex  
RBC  Red blood cell  
RCT  Randomized controlled trial  
RNA  Ribonucleic acid  
RPL  Recurrent pregnancy loss  
RPR  Rapid plasma reagin  
SBO  Small bowel obstruction  
S/D (ratio)  Systolic/diastolic ratio  
SGA  Small for gestational age  
SHBG  Sex hormone-binding globulin  
SLND  Sentinel lymph node dissection  
SNM  Sacral neuromodulation  
SNP  Single-nucleotide polymorphism  
SO  Salpingo-oophorectomy: preceded by R (right) or L (left) or unilateral (U)  
SRM  Spontaneous rupture of membranes  
SSLF  Sacrospinous ligament fixation  
STI  Sexually transmitted infection  
SUI  Stress urinary incontinence  
SS-A, SS-B  Sjogren syndrome A, Sjogren syndrome B
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>SVD</td>
<td>Spontaneous vaginal delivery</td>
</tr>
<tr>
<td>T1DM</td>
<td>Type I diabetes mellitus</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type II diabetes mellitus</td>
</tr>
<tr>
<td>TAH</td>
<td>Total abdominal hysterectomy</td>
</tr>
<tr>
<td>TCGA</td>
<td>The Cancer Genome Atlas</td>
</tr>
<tr>
<td>TESA</td>
<td>Testicular sperm aspiration</td>
</tr>
<tr>
<td>TESE</td>
<td>Testicular sperm extraction</td>
</tr>
<tr>
<td>TLH</td>
<td>Total laparoscopic hysterectomy</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>TOLAC</td>
<td>Trial of labor after cesarean</td>
</tr>
<tr>
<td>TOT</td>
<td>Transobturator tape</td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid-stimulating hormone</td>
</tr>
<tr>
<td>TARA</td>
<td>Transfusion-related acute lung injury</td>
</tr>
<tr>
<td>TTS</td>
<td>Twin-twin transfusion syndrome</td>
</tr>
<tr>
<td>TUNEL</td>
<td>Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labelling</td>
</tr>
<tr>
<td>TVH</td>
<td>Total vaginal hysterectomy</td>
</tr>
<tr>
<td>TVS</td>
<td>Transvaginal sonography</td>
</tr>
<tr>
<td>TVT</td>
<td>Tension-free vaginal tape</td>
</tr>
<tr>
<td>UAE</td>
<td>Uterine artery embolization</td>
</tr>
<tr>
<td>USLF</td>
<td>Uterosacral ligament fixation</td>
</tr>
<tr>
<td>UTI</td>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>VAC</td>
<td>Vincristine, actinomycin-D, cyclophosphamide</td>
</tr>
<tr>
<td>VAIN</td>
<td>Vaginal intraepithelial neoplasia</td>
</tr>
<tr>
<td>VBAC</td>
<td>Vaginal birth after cesarean delivery</td>
</tr>
<tr>
<td>VCUG</td>
<td>Voiding cystourethrography</td>
</tr>
<tr>
<td>VDRL</td>
<td>Venereal disease research laboratory</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VIN</td>
<td>Vulvar intraepithelial neoplasia</td>
</tr>
<tr>
<td>VLPP</td>
<td>Valsalva leak point pressure</td>
</tr>
<tr>
<td>V/Q</td>
<td>Ventilation/Perfusion</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td>VVF</td>
<td>Vesicovaginal fistula</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cell</td>
</tr>
<tr>
<td>WES</td>
<td>Whole exome sequencing</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>ZIFT</td>
<td>Zygote intrafallopian transfer</td>
</tr>
</tbody>
</table>